A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: beta-arrestin2/G-protein coupling antagonists-Reference-Cited by-同舟云学术

A potential novel strategy to separate therapeutic- and side-effects that are mediated via the same receptor: beta-arrestin2/G-protein coupling antagonists

Published:2006-04 Issue:2 Volume:31 Page:119-128
ISSN:0269-4727
Container-title:Journal of Clinical Pharmacy and Therapeutics
language:en
Short-container-title:J Clin Pharm Ther

Author:

Bruns I. R.,Chhum S.,Dinh A. T.,Doerr H.,Dunn N. R.,Ly Y. T.,Mitman C. L.,Rickards H. D.,Sol C.,Wan E. W.,Raffa R. B.

Publisher

Wiley

Subject

Pharmacology (medical),Pharmacology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2710.2006.00714.x/fullpdf

Reference61 articles.

1. The emergence of the drug receptor theory

2. Enhanced Morphine Analgesia in Mice Lacking β-Arrestin 2

3. G Protein-Coupled Receptor Kinase/β-Arrestin Systems and Drugs of Abuse: Psychostimulant and Opiate Studies in Knockout Mice

Cited by 15 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intracerebroventricular administration of CYX-6, a potent μ-opioid receptor agonist, a δ- and κ-opioid receptor antagonist and a biased ligand at μ, δ & κ-opioid receptors, evokes antinociception with minimal constipation and respiratory depression in rats in contrast to morphine;European Journal of Pharmacology;2020-03

2. Striatal overexpression of β-arrestin2 counteracts L-dopa-induced dyskinesia in 6-hydroxydopamine lesioned Parkinson's disease rats;Neurochemistry International;2019-12

3. β-Arrestin Based Receptor Signaling Paradigms: Potential Therapeutic Targets for Complex Age-Related Disorders;Frontiers in Pharmacology;2018-11-28

4. Heterodimerization of the kappa opioid receptor and neurotensin receptor 1 contributes to a novel β-arrestin-2–biased pathway;Biochimica et Biophysica Acta (BBA) - Molecular Cell Research;2016-11

5. Le canal potassique TREK-1 : une cible moléculaire d’intérêt pour le développement d’antalgiques efficaces et bien tolérés;Douleurs : Evaluation - Diagnostic - Traitement;2015-09